- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00148863
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C
August 29, 2007 updated by: French National Agency for Research on AIDS and Viral Hepatitis
Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri
Viral hepatitis C is treated with peg-interferon alpha 2a/2b and ribavirin.
There is no treatment recommended for non responders patients.
This study will evaluate the efficacy, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 Weeks of the addition of interferon gamma in non responders patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Viral hepatitis C is treated with peg-interferon alpha 2a/2b and ribavirin for 24 Weeks.
In many patients, there is no efficacy of this treatment on hepatitis C, and there is no treatment recommended for them.
Interferon gamma has anti-infectious and anti-fibrosis activity.
This study will evaluate the effect, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 Weeks, of the addition of interferon gamma in non responders patients.
65 patients will be included in order to include 27 patients who are non responders after 12 weeks of a second treatment and are eligible to receive interferon gamma.
Patients will then receive peg-interferon alpha 2a (180 micro g once a week, by injection), ribavirin (1,000 to 1,200 mg per day, according to weight) and interferon gamma (100 micro g thrice a week, by injection) during 8 months
Study Type
Interventional
Enrollment
65
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pessac, France, 33604
- Hopital Haut Leveque Service d'Hepato-Gastro-Enterologie
-
Pessac, France, 33604
- Hopital Du Haut-Leveque
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Positive anti-HCV antibodies
- Positive HCV RNA (quantitative method)
- Previous treatment with Peg-interferon alpha 2b 1.0 to 1.5 micro g/kg (during at least 12 weeks) with ribavirin (at least 800 mg/day during at least 12 weeks),stopped since at least 3 months
- Without lower dosage during previous treatment
- Non responder to the previous treatment with Peg-interferon alpha 2b and ribavirin, with detectable HCV RNA at W24 or decrease of less than 2 log10 copies/ml at W12 or decrease greater than 2 log10 but detectable HCV RNA
- Metavir over F2 on the most recent biopsy
- ALT increase over normal value twice during last 6 months
Exclusion Criteria:
- HIV infection
- Psychiatric pathology
- Alcool consummation
- Cirrhosis
- Pregnancy or plan of pregnancy
- Breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)
|
Secondary Outcome Measures
Outcome Measure |
---|
Quality of life
|
Safety
|
Virological response at W72
|
Biochemical response at W72 (ALT below normal value)
|
Immunologic response (CD4 and CD8 HCV specific)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Patrice Couzigou, MD, PhD, Hôpital du Haut-Lévêque, Pessac, France
- Study Director: Genevieve Chene, MD, PhD, INSERM U593, Bordeaux, France
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Study Completion (Actual)
August 1, 2007
Study Registration Dates
First Submitted
September 7, 2005
First Submitted That Met QC Criteria
September 7, 2005
First Posted (Estimate)
September 8, 2005
Study Record Updates
Last Update Posted (Estimate)
August 30, 2007
Last Update Submitted That Met QC Criteria
August 29, 2007
Last Verified
August 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Ribavirin
- Peginterferon alfa-2a
- Interferon alpha-2
- Interferon-gamma
Other Study ID Numbers
- 2004-005033-19
- ANRS HC16 Gammatri
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C, Chronic
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hospices Civils de LyonCompleted
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States, Puerto Rico
Clinical Trials on Peg-interferon alpha 2a (drug)
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Pusan National University HospitalUnknownChronic Hepatitis BKorea, Republic of
-
Centre hospitalier de l'Université de Montréal...Hoffmann-La Roche; Centre de Recherche du Centre Hospitalier de l'Université...Completed
-
Hoffmann-La RocheCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic CancerUnited States
-
Vir Biotechnology, Inc.Alnylam PharmaceuticalsActive, not recruitingChronic Hepatitis BAustralia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
-
M.D. Anderson Cancer CenterCompleted
-
Arbutus Biopharma CorporationActive, not recruitingChronic Hepatitis bUnited States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
-
Hoffmann-La RocheCompletedHealthy VolunteersNew Zealand, Taiwan, Australia, Hong Kong, Singapore
-
Brooke Army Medical CenterHoffmann-La Roche; The Geneva FoundationCompletedHepatitis C | Fatty LiverUnited States